LIFE CODE specializes in the precise diagnosis of hematologic neoplasms, implementing conventional cytogenetics, FISH analysis, and correlation of specific molecular markers with different types of hematologic malignancies.
Initial diagnosis is based on microscopic analysis of malignant cells isolated from various tissues such as peripheral blood, pleural fluid, bone marrow, and solid tumor biopsies (e.g., lymph node tumors).
Conventional cytogenetic analysis remains the primary genetic method in hematology. However, FISH (Fluorescence In Situ Hybridization) serves as a crucial complementary tool in cases where:
There is a high frequency of false-negative (normal) karyotypes
Clinical and hematologic data point to a specific chromosomal abnormality despite a normal karyotype
Conventional cytogenetic analysis is not feasible due to lack of metaphases or sample type, e.g., biopsies
Further investigation of complex chromosomal rearrangements is required
Chimerism needs to be studied post allogeneic transplantation
Specific chromosomal abnormalities, along with their hybrid genes, are recognized by the WHO classification of malignancies and, combined with cellular morphology, biopsy results, immunophenotyping, and clinical features, enable precise discrimination between different neoplasms.
Additionally, associating specific molecular markers with different types of hematologic neoplasms contributes to accurate diagnosis, prognosis determination, and disease monitoring—factors crucial in therapeutic decision-making.
DISEASES
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Chronic Myeloid Leukemia (CML)
Idiopathic Thrombocythemia (ET)
Chronic Neutrophilic Leukemia (CNL)
Chronic Eosinophilic Leukemia (CEL) / Idiopathic Hypereosinophilic Syndrome (iHES)
Chronic Idiopathic Myelofibrosis (CIMF)
Myeloid neoplasms associated with eosinophilia and PDGFRA, PDGFRB, or FGFR1 gene rearrangements